Form 4: Bausch & Lomb EVP of R&D and CMO, Yehia Hashad, Reports Stock and Option Grants

Yehia Hashad, EVP of R&D and CMO at Bausch & Lomb, reports the acquisition of restricted stock units and stock options.

Summary

• Yehia Hashad, EVP of R&D and CMO of Bausch & Lomb Corporation, filed a Form 4 on March 1, 2024, reporting changes in beneficial ownership.
• On February 28, 2024, Hashad acquired 20,973 common shares through restricted stock units (RSUs) and 63,516 stock options.
• The RSUs vest in three equal installments annually from the grant date, contingent on continued service.
• The stock options also vest in three equal annual installments from the grant date and expire ten years from the grant date.
• The exercise price for the stock options is $16.85.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects standard executive compensation practices, indicating confidence in the executive's role and future performance. There are no red flags or negative implications.

Positives

• The grant of RSUs and stock options suggests confidence in Hashad's continued contributions to Bausch & Lomb.
• The vesting schedules of both RSUs and stock options incentivize long-term performance and retention.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the RSUs and stock options.

Industry Context

This filing is a routine disclosure of executive compensation in the form of equity grants, which is a common practice in publicly traded companies to align management's interests with those of shareholders.

Comparison to Industry Standards

• Equity grants are a standard component of executive compensation packages in the pharmaceutical and medical device industries.
• Companies like Johnson & Johnson, Novartis, and Abbott Laboratories also utilize stock options and restricted stock units to incentivize their executives.
• The vesting schedules and exercise prices are typically structured to align with long-term performance goals and shareholder value creation.

Stakeholder Impact

• The equity grants align management's interests with those of shareholders, potentially driving long-term value creation.
• Employees may view the grants as a positive sign of the company's commitment to its leadership.

Key Dates